Abstract:Rationale: Protein arginine methyltransferase 5 (PRMT5) is an oncogene that promotes tumor cell proliferation, invasion and metastasis. However, the underlying mechanisms by which PRMT5 contributes to the progression of cervical cancer and especially the tumor microenvironment remain poorly understood. Methods: PRMT5 expression level was analyzed by Q-PCR, western blot, immunohistochemistry, and TCGA database. The role of PRMT5 in tumor growth was observed by transplanted tumor models, and the function of T cells in tumor microenvironment and in vitro co-culture system was investigated through flow cytometry. The transcriptional regulation of PRMT5 was analyzed using luciferase reporter and chromatin immunoprecipitation (ChIP) assay. The therapeutic effect of PRMT5 inhibitor was evaluated in a cervical cancer cell line transplanted tumor model. Results: We observed that the mRNA and protein expression levels of PRMT5 were increased in cervical cancer tissues, and the high expression of PRMT5 was associated with poor outcomes in cervical cancer patients. The absence of PRMT5 significantly inhibited tumor growth in a cervical cancer transplanted tumor model, and importantly, PRMT5 absence in tumors led to increase the number and enhance the function of tumor infiltrating T cells. Mechanistically, PRMT5 enhanced the transcription of STAT1 through symmetric dimethylation of histone H3R2 and thus promoted PD-L1 expression in cervical cancer cells. Moreover, in an in vitro co-culture system, knockdown of PRMT5 in tumor cells could directly enhance the expression of IFN-γ, TNF-α and granzyme B in T cells. These results suggested that PRMT5 promoted the development of cervical cancer by the crosstalk between tumor cells and T cells. Furthermore, the PRMT5 inhibitor EPZ015666 treatment could suppress tumor growth in a cervical cancer transplanted tumor model. Conclusion: Our results clarify a new mechanism which PRMT5 knockdown in cervical cancer cells drives an antitumor function via reprogramming T cell-mediated response and regulating PD-L1 expression. Thus, our study highlights that PRMT5 may be a potential target for cervical cancer therapy.

Protein Arginine Methyltransferases 5 (PRMT5) Affect Multiple Stages of Autophagy and Modulate Autophagy-related Genes in Controlling Breast Cancer Tumorigenesis.

Autophagy dictates sensitivity to PRMT5 inhibitor in breast cancer

Protein Arginine Methyltransferase 5: a Potential Cancer Therapeutic Target

PRMT5 Determines the Sensitivity to Chemotherapeutics by Governing Stemness in Breast Cancer

Protein Arginine Methyltransferase 5 Confers the Resistance of Triple-Negative Breast Cancer to Nanoparticle Albumin-Bound Paclitaxel by Enhancing Autophagy Through the Dimethylation of ULK1

PRMT5 Promotes Epithelial‐mesenchymal Transition Via EGFR‐β‐catenin Axis in Pancreatic Cancer Cells

PRMT5 activates AKT via methylation to promote tumor metastasis

Elevated Expression of Protein Arginine Methyltransferase 5 Predicts the Poor Prognosis of Breast Cancer

PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression

Arginine methyltransferase PRMT5 methylates and stabilizes KLF5 via decreasing its phosphorylation and ubiquitination to promote basal-like breast cancer

PRMT1 Promotes Neuroblastoma Cell Survival Through ATF5.

Protein arginine methyltransferase 5 (PRMT5) activates WNT/β‐catenin signalling in breast cancer cells via epigenetic silencing of DKK1 and DKK3

The Methylation Induced by Protein Arginine Methyltransferase 5 Promotes Tumorigenesis and Progression of Lung Cancer.

PRMT5-exacerbating tumor stemness and immunosuppression confer a novel immunotherapeutic vulnerability in aggressive prostate cancer

Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling

Protein arginine methyltransferase 5 regulates multiple signaling pathways to promote lung cancer cell proliferation

Protein Arginine Methyltransferases (PRMTs): Orchestrators of Cancer Pathogenesis, Immunotherapy Dynamics, and Drug Resistance

PRMT5 prognostic value in cancer

PRMT5 Inhibition Promotes PD-L1 Expression and Immuno-Resistance in Lung Cancer

Automethylation of Protein Arginine Methyltransferase 7 and Its Impact on Breast Cancer Progression

PRMT5: a putative oncogene and therapeutic target in prostate cancer